Long-term Outcomes of Monascin - a Novel Dual Peroxisome Proliferator-activated Receptor γ/nuclear Factor-erythroid 2 Related Factor-2 Agonist in Experimental Intracerebral Hemorrhage

Overview

Journal Ther Adv Neurol Disord

Specialty Neurology

Date 2020 Jun 2

PMID 32477427

Citations 11

Authors

Pengcheng Fu

Jiachen Liu

Qinqin Bai

Xingang Sun

Zhenjia Yao

Lirong Liu

Cuimei Wu

Gaiqing Wang

Affiliations

Soon will be listed here.

Abstract

Background: Hematoma is the chief culprit in brain injury following intracranial cerebral hemorrhage (ICH). Noninvasive hematoma clearance could be an option to prevent and alleviate early brain injury after ICH. Peroxisome proliferator-activated receptor γ (PPAR-γ) and nuclear factor-erythroid 2 related factor-2 (Nrf2) facilitate removal of hematoma in ICH. Monascin acts as the natural Nrf2 activator with PPAR-γ agonist, and the long-term effects of monascin following ICH have not been elucidated.

Methods: ICH in rats was induced by stereotactic, intrastriatal injection of type IV collagenase. Monascin was administered twice daily by gastric perfusion for 14 days after ICH induction. Long-term neurological scores (T maze, Garcia scales, rotor rod test, and Morris water maze), hematoma volume, as well as iron overload around hematoma and brain atrophy were evaluated at 7, 14, and 28 days after ICH.

Results: The results showed that monascin improved long-term neurological deficits, spatial memory performance, learning ability, and brain shrinkage after ICH. Monascin also reduced hematoma volume at 7 days and iron content at 7 and 14 days after ICH.

Conclusion: PPAR γ and Nrf2 play a crucial role in hematoma clearance after ICH in rat. As a dual agonist of PPAR γ and Nrf2, monascin improved long-term outcomes by facilitating hematoma clearance, and by attenuating iron overload and brain atrophy after experimental ICH.

Citing Articles

Nrf2 activators for the treatment of rare iron overload diseases: From bench to bedside.

Dong Y, Zheng M, Ding W, Guan H, Xiao J, Li F Redox Biol. 2025; 81:103551.

PMID: 39965404 PMC: 11876910. DOI: 10.1016/j.redox.2025.103551.

Mas receptor activation facilitates innate hematoma resolution and neurological recovery after hemorrhagic stroke in mice.

Deng X, Ren J, Chen K, Zhang J, Zhang Q, Zeng J J Neuroinflammation. 2024; 21(1):106.

PMID: 38658922 PMC: 11041011. DOI: 10.1186/s12974-024-03105-8.

Research progress of endogenous hematoma absorption after intracerebral hemorrhage.

Fu P, Zhang M, Wu M, Zhou W, Yin X, Chen Z Front Neurol. 2023; 14:1115726.

PMID: 36970539 PMC: 10036389. DOI: 10.3389/fneur.2023.1115726.

Neuroprotection by Nrf2 via modulating microglial phenotype and phagocytosis after intracerebral hemorrhage.

Liang C, Liu L, Bao S, Yao Z, Bai Q, Fu P Heliyon. 2023; 9(2):e13777.

PMID: 36852060 PMC: 9957781. DOI: 10.1016/j.heliyon.2023.e13777.

Elucidating the progress and impact of ferroptosis in hemorrhagic stroke.

Pan F, Xu W, Ding J, Wang C Front Cell Neurosci. 2023; 16:1067570.

PMID: 36713782 PMC: 9874704. DOI: 10.3389/fncel.2022.1067570.

References

Mendelow A, Gregson B, Rowan E, Murray G, Gholkar A, Mitchell P . Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013; 382(9890):397-408. PMC: 3906609. DOI: 10.1016/S0140-6736(13)60986-1. View

Wang G, Guo Z, Tong L, Xue F, Krafft P, Budbazar E . TLR7 (Toll-Like Receptor 7) Facilitates Heme Scavenging Through the BTK (Bruton Tyrosine Kinase)-CRT (Calreticulin)-LRP1 (Low-Density Lipoprotein Receptor-Related Protein-1)-Hx (Hemopexin) Pathway in Murine Intracerebral Hemorrhage. Stroke. 2018; 49(12):3020-3029. DOI: 10.1161/STROKEAHA.118.022155. View

Zhao X, Sun G, Zhang J, Strong R, Song W, Gonzales N . Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol. 2007; 61(4):352-62. DOI: 10.1002/ana.21097. View

Babu R, Bagley J, Di C, Friedman A, Adamson C . Thrombin and hemin as central factors in the mechanisms of intracerebral hemorrhage-induced secondary brain injury and as potential targets for intervention. Neurosurg Focus. 2012; 32(4):E8. DOI: 10.3171/2012.1.FOCUS11366. View

Tontonoz P, Nagy L, Alvarez J, Thomazy V, Evans R . PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998; 93(2):241-52. DOI: 10.1016/s0092-8674(00)81575-5. View

Zhao X, Grotta J, Gonzales N, Aronowski J . Hematoma resolution as a therapeutic target: the role of microglia/macrophages. Stroke. 2008; 40(3 Suppl):S92-4. DOI: 10.1161/STROKEAHA.108.533158. View

Wang G, Wang L, Sun X, Tang J . Haematoma scavenging in intracerebral haemorrhage: from mechanisms to the clinic. J Cell Mol Med. 2017; 22(2):768-777. PMC: 5783832. DOI: 10.1111/jcmm.13441. View

Akihisa T, Tokuda H, Ukiya M, Kiyota A, Yasukawa K, Sakamoto N . Anti-tumor-initiating effects of monascin, an azaphilonoid pigment from the extract of Monascus pilosus fermented rice (red-mold rice). Chem Biodivers. 2006; 2(10):1305-9. DOI: 10.1002/cbdv.200590101. View

Wang G, Hu W, Tang Q, Wang L, Sun X, Chen Y . Effect Comparison of Both Iron Chelators on Outcomes, Iron Deposit, and Iron Transporters After Intracerebral Hemorrhage in Rats. Mol Neurobiol. 2015; 53(6):3576-3585. DOI: 10.1007/s12035-015-9302-3. View

10.

Durocher M, Ander B, Jickling G, Hamade F, Hull H, Knepp B . Inflammatory, regulatory, and autophagy co-expression modules and hub genes underlie the peripheral immune response to human intracerebral hemorrhage. J Neuroinflammation. 2019; 16(1):56. PMC: 6399982. DOI: 10.1186/s12974-019-1433-4. View

11.

Vespa P, Hanley D, Betz J, Hoffer A, Engh J, Carter R . ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for Brain Hemorrhage: A Multicenter Randomized Controlled Trial. Stroke. 2016; 47(11):2749-2755. PMC: 6168060. DOI: 10.1161/STROKEAHA.116.013837. View

12.

Mould W, Carhuapoma J, Muschelli J, Lane K, Morgan T, McBee N . Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke. 2013; 44(3):627-34. PMC: 4124642. DOI: 10.1161/STROKEAHA.111.000411. View

13.

Wang J, Wang G, Yi J, Xu Y, Duan S, Li T . The effect of monascin on hematoma clearance and edema after intracerebral hemorrhage in rats. Brain Res Bull. 2017; 134:24-29. DOI: 10.1016/j.brainresbull.2017.06.018. View

14.

Sugiyama T, Imai T, Nakamura S, Yamauchi K, Sawada S, Shimazawa M . A novel Nrf2 activator, RS9, attenuates secondary brain injury after intracerebral hemorrhage in sub-acute phase. Brain Res. 2018; 1701:137-145. DOI: 10.1016/j.brainres.2018.08.021. View

15.

Hsu W, Pan T . A novel PPARgamma agonist monascin's potential application in diabetes prevention. Food Funct. 2014; 5(7):1334-40. DOI: 10.1039/c3fo60575b. View

16.

Zhao X, Sun G, Ting S, Song S, Zhang J, Edwards N . Cleaning up after ICH: the role of Nrf2 in modulating microglia function and hematoma clearance. J Neurochem. 2014; 133(1):144-52. PMC: 4361377. DOI: 10.1111/jnc.12974. View

17.

Wang G, Li T, Duan S, Dong L, Sun X, Xue F . PPAR- Promotes Hematoma Clearance through Haptoglobin-Hemoglobin-CD163 in a Rat Model of Intracerebral Hemorrhage. Behav Neurol. 2018; 2018:7646104. PMC: 6079602. DOI: 10.1155/2018/7646104. View

18.

Hanley D, Thompson R, Rosenblum M, Yenokyan G, Lane K, McBee N . Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019; 393(10175):1021-1032. PMC: 6894906. DOI: 10.1016/S0140-6736(19)30195-3. View